What happened with JSPR today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Jasper Therapeutics is a clinical-stage biotechnology company whose operating plan centers on briquilimab for chronic urticaria, or persistent hives. This antibody is designed to block a survival signal received through the KIT protein, reducing the mast cells involved in these diseases. Jasper has narrowed its work to chronic urticaria, halted enrollment in its asthma study and discontinued its former stem-cell-transplant programs.
Jasper has no approved products and earns no product-sales revenue. It aims to bring briquilimab to market, but cannot market or promote it before FDA or comparable foreign regulatory approval. Its business therefore depends on completing development and raising additional capital to fund the work; it has no committed source of additional financing.
The company holds worldwide exclusive rights to develop and commercialize briquilimab under its Amgen license. It has no manufacturing facilities and relies on Lonza as a single-source supplier for clinical material. Changing suppliers is constrained by consent requirements under its Lonza and Amgen agreements.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Jasper’s prospects hinge on briquilimab’s clinical success and funding; watch Lonza too, because its manufacturing agreement restricts alternative supply arrangements.
Celldex directly challenges Jasper’s briquilimab by developing another antibody targeting KIT for mast-cell diseases. Watch its efficacy and safety results in chronic urticaria, but do not treat them as proof of how briquilimab will perform: Jasper says anti-KIT antibodies can behave differently.
Evommune’s EVO756 competes for chronic spontaneous urticaria patients Jasper aims to treat with briquilimab, using a small molecule that blocks MRGPRX2 rather than an anti-KIT antibody. Watch its Phase 2b trial in patients whose disease resists antihistamines, particularly the change in urticaria activity after 12 weeks of treatment.
Sanofi competes with Jasper’s briquilimab in mast-cell diseases through an antibody targeting IL-4 receptor alpha, rather than KIT. Its efficacy and safety results in these diseases matter for whether briquilimab can offer patients a better treatment despite the different mechanism.
Novartis competes for the same mast-cell disease treatment opportunity as Jasper’s briquilimab, developing a small molecule that inhibits Bruton’s tyrosine kinase (BTK) rather than an anti-KIT antibody. Watch its progress toward approval: a rival reaching patients first could reduce Jasper’s commercial opportunity.
Jasper Therapeutics, Inc. earningsThis company
Jasper Therapeutics’ report will show whether progress in its urticaria program is keeping pace with the cash it is using to develop briquilimab.
Read clinical-program progress alongside cash used in operations. Progress in the urticaria trials with cash use under control would support continuing briquilimab’s development on its current path. Little progress while cash continues to flow out heavily would make financing more urgent and could force delays or cuts to the program.
